Chronic lymphocytic leukemia is one of the most common leukemias in the western world and consists of many chromosome aberrations. We report the case of a 74-year-old male patient with chronic lymphocytic leukemia with complex variant translocations t(8;22)(q24;q11) and der(8)t(6;8)(p21;p21) identified by chromosome banding analysis and confirmed by fluorescence in situ hybridization analysis o...

Trisomy 12 represents the third most frequent chromosomal aberration in chronic lymphocytic leukemia (CLL) (1520% of cases) and often (approx. 60% of cases) occurs as the sole cytogenetic lesion. Within the hierarchical model of genetic subgroups commonly used in clinical practice, +12 as single aberration confers an intermediate prognostic risk, with a median time to progression of 33 months a...

Submit Manuscript | http://medcraveonline.com Abbreviations: CLL: Chronic Lymphocytic Leukemia; FCR: Fludarabine, Cyclophosphamide and Rituximab; PI3K: Phosphatidylinositol 3-kinase; IWCLL: International Workshop on Chronic Lymphocytic Leukemia; CIRS: Cumulative Illness Rating Scale; CIT: chemoimmunotherapy; FISH: Fluorescence In Situ Hybridization; PFS: Progression Free Survival; EMA: European...

Ofatumumab Arzerra® is a human monoclonal antibody, which induces killing of a panel of tumor B-cell lines and primary tumor cells by the activation of in vitro complement-dependent cytotoxicity and antibody-dependent, cell-mediated cytotoxicity. The humanized anti-CD20 monoclonal antibody has been approved by the US Food and Drug Administration for the treatment of chronic lymphocytic leukemia...

We report a case of progressive multifocal leukoencephalopathy developing in a fludarabine-naïve patient with chronic lymphocytic leukemia. We suggest that progressive multifocal leukoencephalopathy should be considered in any chronic lymphocytic leukemia patient with unexplained neurological symptoms. Treatment history does not necessarily require fludarabine. Intrathecal cytosine arabinoside ...

The activities of thymidine kinase (TK) isoenzyme 1 and 2 were examined in extracts of human benign or malignant lymphoid tissue and correlated with degrees of morphological differentiation. TK2 activity occurred in peripheral blood lym phocytes of normal individuals, patients with chronic lymphocytic leukemia, or solid lymphoid tissue, exhibiting either nonneoplastic histological findings or t...

This update of early stage B-cell chronic lymphocytic leukemia (B-CLL) embraces current information on the diagnosis, biology, and intervention required to more fully develop algorithms for management of this disease. Emphasis on early stage is based on the rapid advancement in our understanding of the disease parameters and our increasing ability to predict for a given early stage patient whet...

© Fe rra ta St ort i F ou nd ati on this on-site documentation, causes of death were grouped into the following categories: therapy-related, CLL-related, CLL-unrelated, or unknown. Both studies were approved by the Institutional Review Board and Ethics Committee of the University of Munich and performed in accordance with the Declaration of Helsinki. Comorbidity assessment For both trials, como...

The authors describe a 51-year-old man with chronic lymphocytic leukemia who presented with respiratory distress and then died suddenly while in hospital. Autopsy revealed pulmonary leukostasis and a large intracardiac mass containing mostly mature lymphocytes and fibrin. Although leukostasis and lymphocyte thrombi have been described (albeit rarely) in chronic lymphocytic leukemia, an intracar...

The activities of thymidine kinase (TK) isoenzyme 1 and 2 were examined in extracts of human benign or malignant lymphoid tissue and correlated with degrees of morphological differentiation. TK2 activity occurred in peripheral blood lymphocytes of normal individuals, patients with chronic lymphocytic leukemia, or solid lymphoid tissue, exhibiting either nonneoplastic histological findings or th...